Prentice Wealth Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-11,451
Closed -$278K 115
2025
Q2
$278K Sell
11,451
-6,416
-36% -$150K 0.07% 104
2025
Q1
$453K Buy
17,867
+175
+1% +$4.58K 0.13% 84
2024
Q4
$469K Buy
17,692
+1,481
+9% +$40.2K 0.14% 82
2024
Q3
$469K Buy
16,211
+3,022
+23% +$88.2K 0.14% 83
2024
Q2
$369K Buy
13,189
+37
+0.3% +$1.02K 0.12% 86
2024
Q1
$365K Buy
13,152
+1,390
+12% +$38.6K 0.13% 86
2023
Q4
$339K Buy
11,762
+239
+2% +$7.22K 0.13% 86
2023
Q3
$382K Buy
11,523
+150
+1% +$5.3K 0.17% 73
2023
Q2
$417K Buy
11,373
+3,223
+40% +$125K 0.19% 70
2023
Q1
$333K Sell
8,150
-25
-0.3% -$1.08K 0.16% 78
2022
Q4
$419K Buy
8,175
+690
+9% +$33.1K 0.21% 55
2022
Q3
$328K Buy
+7,485
New +$364K 0.18% 61
2022
Q2
Sell
-6,157
Closed -$320K 175
2022
Q1
$320K Buy
6,157
+272
+5% +$14.1K 0.15% 66
2021
Q4
$351K Sell
5,885
-125
-2% -$6.19K 0.16% 64
2021
Q3
$258K Sell
6,010
-89
-1% -$3.94K 0.12% 84
2021
Q2
$239K Buy
6,099
+2,032
+50% +$79K 0.12% 92
2021
Q1
$147K Buy
+4,067
New +$144K 0.08% 108

Other funds holding PFE

Prentice Wealth Management's PFE Position: Q3 2025 in Review

Prentice Wealth Management sold out of Pfizer (PFE) in Q3 2025, closing a stake of 11,451 shares — an estimated $278K sold.

Prentice Wealth Management first reported a position in PFE in Q1 2021 and held it in 17 quarters. The position peaked at $469K in Q4 2024. 2,811 funds tracked by Wall St. Rank hold PFE as of Q3 2025.

  • Prentice Wealth Management reported no remaining Pfizer position as of Q3 2025 after selling out during the quarter.
  • Prentice Wealth Management sold 11,451 Pfizer shares in Q3 2025, an estimated $278K.
  • Prentice Wealth Management first reported a position in Pfizer in Q1 2021 and held it in 17 quarters.
  • Prentice Wealth Management's Pfizer position peaked at $469K in Q4 2024.
  • 2,811 funds tracked by Wall St. Rank held Pfizer as of Q3 2025.

Based on Prentice Wealth Management's 13F filing for Q3 2025, filed 9 Oct 2025.